Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Tuesday, 12 / 12 / 2017

Articles

Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease

REVIEW ARTICLE

Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease

Mark CC Cheah1, Arthur J McCullough2,3 and George Boon-Bee Goh*1,4

1Department of Gastroenterology & Hepatology, Singapore General Hospital, Singapore
2Department of Gastroenterology, Cleveland Clinic, Ohio, USA
3Department of Pathobiology, Cleveland Clinic, Ohio, USA
4Duke-NUS Medical School, Singapore

*Correspondence to: Dr George Boon-Bee Goh, Department of Gastroenterology & Hepatology, Singapore General Hospital, 20 College Road, Singapore 169856, Singapore. Tel: +65-62223322, Fax: +65-62273623, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2017;5(3):261-271 DOI: 10.14218/JCTH.2017.00009
Received: February 12, 2017 Accepted: April 29, 2017 Published online: June 24, 2017

Abstract

Non-alcoholic fatty liver disease (NAFLD) is a burgeoning global health concern. In the subset of NAFLD patients with non-alcoholic steatohepatitis (NASH), the presence of significant fibrosis at index assessment is associated with poor prognosis and increased mortality. Hence, there is a growing need to accurately assess and stage fibrosis. Liver biopsy, the current gold standard, has limitations with sampling error and is invasive, with associated inherent risk. This has led to a host of non-invasive means of assessing fibrosis, which has garnered relevance in a disease that requires serial assessment of fibrosis longitudinally over time. This review discusses, comprehensively, the various tools available to the clinician for the assessment of fibrosis, including the various scoring systems used in liver biopsy, the non-invasive means of serum biomarkers, such as the highly-validated NAFLD fibrosis score, and the imaging-based modalities, such as transient elastography and magnetic resonance elastography.

Keywords

NAFLD, Fibrosis assessment, Modalities

 

Journal of Clinical and Translational Hepatology 2017 vol. 5, 261-271  Html ] [ PDF Full-text ]

 

© The Authors 2017. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

 

 logo

You are here: Home